Ruud Houben
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ruud Houben has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Catharina M. L. Zegers
Department of Radiation Oncology (MAASTRO), GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre , Maastricht
3 shared publications - Danielle B. P. Eekers
Department of Radiation Oncology (MAASTRO), GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre , Maastricht
3 shared publications - Inge Compter
Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre +, Doctor Tanslaan 12, 6229 ET Maastricht, the Netherlands
3 shared publications - Lizza Elisabeth Lucia Hendriks
Department of Pulmonary Diseases, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, The Netherlands
3 shared publications - Rianne D. W. Vaes
Department of Radiation Oncology (Maastro Clinic), GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands
3 shared publications David Hofstede
2 shared publications
Latest Publications
- Open Access
- 10 May 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 39
Trade-offs in proton and photon radiotherapy for pituitary adenomas
- 10 May 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 39
Open AccessTrade-offs in proton and photon radiotherapy for pituitary adenomas
- Open Access
- 22 March 2026
- Published by Elsevier in Technical Innovations & Patient Support in Radiation Oncology
- Vol. 38, 100393
Dosimetric comparison of the shoulder region between paired photon and proton plans in breast cancer patients
- 22 March 2026
- Published by Elsevier in Technical Innovations & Patient Support in Radiation Oncology
- Vol. 38, 100393
Open AccessDosimetric comparison of the shoulder region between paired photon and proton plans in breast cancer patients
- 10 October 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (3) , 1836-1846
Association of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) with survival in patients with oligometastatic non-small-cell lung cancer treated with immunotherapy: a multicentre retrospective study
Purpose Current guidelines recommend adding local radical therapy (LRT) to systemic treatment in synchronous oligometastatic non-small-cell lung cancer (sOM-NSCLC), but survival data on immunotherapy-based regimens are limited. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are prognostic in NSCLC, with higher values linked to worse outcomes. This study examines their association with survival in sOM-NSCLC patients treated with immunotherapy. Methods We conducted a multicenter retrospective study including all consecutive patients with [18F]FDG-PET and brain imaging-staged sOM-NSCLC, between 2015 and 2022, who received first-line (chemo)-immunotherapy and had baseline PET-scan available for review. Subgroups were analyzed based on median MTV and TLG values (high vs. low: H-MTV vs. L-MTV, H-TLG vs. L-TLG). Study endpoints were progression-free survival (PFS) and overall survival (OS), according to MTV and TLG distribution (high vs. low), in the overall population (primary endpoint) and in relation to LRT and systemic treatment type (secondary endpoints). Results 105 patients were included, 50% were male and 73% had non-squamous histology, median age was 64.9 years. Median PFS was significantly longer for L-MTV vs. H-MTV (14.73 months (95%CI, 7.06–22.40) vs. 7.63 months (95%CI, 5.73–9.52), p = 0.028), but also LRT was associated with PFS (19.04 months (95%CI, 8.47–29.60) versus 7.46 months (95%CI, 5.25–9.67), p = 0.045), while neither MTV nor TLG had impact on OS. In multivariate analysis, only PD-L1 < 50% and soft tissue metastases remained significantly associated with shorter PFS. Conclusions Baseline MTV is preliminarily associated with PFS in sOM-NSCLC patients treated with immunotherapy, but results are exploratory and need prospective validation in larger cohorts.
- 10 October 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (3) , 1836-1846
Association of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) with survival in patients with oligometastatic non-small-cell lung cancer treated with immunotherapy: a multicentre retrospective study
Purpose Current guidelines recommend adding local radical therapy (LRT) to systemic treatment in synchronous oligometastatic non-small-cell lung cancer (sOM-NSCLC), but survival data on immunotherapy-based regimens are limited. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are prognostic in NSCLC, with higher values linked to worse outcomes. This study examines their association with survival in sOM-NSCLC patients treated with immunotherapy. Methods We conducted a multicenter retrospective study including all consecutive patients with [18F]FDG-PET and brain imaging-staged sOM-NSCLC, between 2015 and 2022, who received first-line (chemo)-immunotherapy and had baseline PET-scan available for review. Subgroups were analyzed based on median MTV and TLG values (high vs. low: H-MTV vs. L-MTV, H-TLG vs. L-TLG). Study endpoints were progression-free survival (PFS) and overall survival (OS), according to MTV and TLG distribution (high vs. low), in the overall population (primary endpoint) and in relation to LRT and systemic treatment type (secondary endpoints). Results 105 patients were included, 50% were male and 73% had non-squamous histology, median age was 64.9 years. Median PFS was significantly longer for L-MTV vs. H-MTV (14.73 months (95%CI, 7.06–22.40) vs. 7.63 months (95%CI, 5.73–9.52), p = 0.028), but also LRT was associated with PFS (19.04 months (95%CI, 8.47–29.60) versus 7.46 months (95%CI, 5.25–9.67), p = 0.045), while neither MTV nor TLG had impact on OS. In multivariate analysis, only PD-L1 < 50% and soft tissue metastases remained significantly associated with shorter PFS. Conclusions Baseline MTV is preliminarily associated with PFS in sOM-NSCLC patients treated with immunotherapy, but results are exploratory and need prospective validation in larger cohorts.
- Open Access
- 23 April 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 53, 100963
Microscopic intramural spread in patients with rectal cancer after neoadjuvant chemoradiation
- 23 April 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 53, 100963
Open AccessMicroscopic intramural spread in patients with rectal cancer after neoadjuvant chemoradiation
- Open Access
- 14 April 2025
- Published by Elsevier in Lung Cancer
- Vol. 203, 108541
Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model
- 14 April 2025
- Published by Elsevier in Lung Cancer
- Vol. 203, 108541
Open AccessChemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model
- Open Access
- 8 February 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 52, 100929
The effect of radiation dose to the brain on early self-reported cognitive function in brain and head-and-neck cancer patients
- 8 February 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 52, 100929
Open AccessThe effect of radiation dose to the brain on early self-reported cognitive function in brain and head-and-neck cancer patients
- 27 January 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (5) , 109639
Risk factors and prognostic factors of pleural metastases in thymic epithelial tumors: A narrative review
- 27 January 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (5) , 109639
Risk factors and prognostic factors of pleural metastases in thymic epithelial tumors: A narrative review
- 24 June 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 198, 110409
Robustness of intensity modulated proton treatment of esophageal cancer for anatomical changes and breathing motion
- 24 June 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 198, 110409
Robustness of intensity modulated proton treatment of esophageal cancer for anatomical changes and breathing motion
- Open Access
- 14 April 2024
- Published by Elsevier in Technical Innovations & Patient Support in Radiation Oncology
- Vol. 30, 100250
The existence of cranial bone flap displacement during brain radiotherapy
- 14 April 2024
- Published by Elsevier in Technical Innovations & Patient Support in Radiation Oncology
- Vol. 30, 100250
Open AccessThe existence of cranial bone flap displacement during brain radiotherapy
- 20 October 2023
- Published by Elsevier in Annals of Oncology
- Vol. 34, S749
1301P A prognostic clinical and circulating biomarker model to identify futile chemo-radiotherapy (CRT) in stage III NSCLC
- 20 October 2023
- Published by Elsevier in Annals of Oncology
- Vol. 34, S749
1301P A prognostic clinical and circulating biomarker model to identify futile chemo-radiotherapy (CRT) in stage III NSCLC